Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
1
33%
Ph phase_2
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(2)
Other(1)

Detailed Status

Completed2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 21 (50.0%)
N/A1 (50.0%)

Trials by Status

unknown133%
completed267%

Recent Activity

0 active trials
Showing 3 of 3
completed

Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2

NCT01160705
unknownnot_applicable

CTC Detection Rate in SCCHN With a in Vivo Device

NCT03071900
completedphase_2

Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases

NCT00967031

Clinical Trials (3)

Showing 3 of 3 trials
NCT01160705

Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2

Completed
NCT03071900Not Applicable

CTC Detection Rate in SCCHN With a in Vivo Device

Unknown
NCT00967031Phase 2

Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases

Completed

All 3 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
3